|
1
|
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim
JH, Kim JW and Kim S: MicroRNA expression profiles in serous
ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cittelly DM, Dimitrova I, Howe EN,
Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR,
Spillman MA, et al: Restoration of miR-200c to ovarian cancer
reduces tumor burden and increases sensitivity to paclitaxel. Mol
Cancer Ther. 11:2556–2565. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pal MK, Jaiswar SP, Dwivedi VN, Tripathi
AK, Dwivedi A and Sankhwar P: MicroRNA: A new and promising
potential biomarker for diagnosis and prognosis of ovarian cancer.
Cancer Biol Med. 12:328–341. 2015.PubMed/NCBI
|
|
4
|
Lupia M and Cavallaro U: Ovarian cancer
stem cells: Still an elusive entity? Mol Cancer. 16:642017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koutsaki M, Libra M, Spandidos DA and
Zaravinos A: The miR-200 family in ovarian cancer. Oncotarget.
8:66629–66640. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Y, Xu C, Wang Y and Zhang X:
MicroRNA-365 inhibits ovarian cancer progression by targeting
Wnt5a. Am J Cancer Res. 7:1096–1106. 2017.PubMed/NCBI
|
|
7
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chan E, Prado DE and Weidhaas JB: Cancer
microRNAs: From subtype profiling to predictors of response to
therapy. Trends Mol Med. 17:235–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hata A and Lieberman J: Dysregulation of
microRNA biogenesis and gene silencing in cancer. Sci Signal.
8:re32015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saumet A and Lecellier CH: MicroRNAs and
personalized medicine: Evaluating their potential as cancer
biomarkers. Adv Exp Med Biol. 888:5–15. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Srivastava SK, Arora S, Averett C, Singh S
and Singh AP: Modulation of microRNAs by phytochemicals in cancer:
Underlying mechanisms and translational significance. BioMed Res
Int. 2015:8487102015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Virant-Klun I, Ståhlberg A, Kubista M and
Skutella T: MicroRNAs: From female fertility, germ cells, and stem
cells to cancer in humans. Stem Cells Int. 2016:39849372016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kinose Y, Sawada K, Nakamura K and Kimura
T: The role of microRNAs in ovarian cancer. BioMed Res Int.
2014:2493932014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Kim S and Kim IM: Regulation of
metastasis by microRNAs in ovarian cancer. Front Oncol. 4:1432014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garofalo M, Quintavalle C, Romano G, Croce
CM and Condorelli G: miR221/222 in cancer: Their role in tumor
progression and response to therapy. Curr Mol Med. 12:27–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wei Y, Yang J, Yi L, Wang Y, Dong Z, Liu
Z, Ou-Yang S, Wu H, Zhong Z, Yin Z, et al: MiR-223-3p targeting
SEPT6 promotes the biological behavior of prostate cancer. Sci Rep.
4:75462014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fu X, Li Y, Alvero A, Li J, Wu Q, Xiao Q,
Peng Y, Hu Y, Li X, Yan W, et al: MicroRNA-222-3p/GNAI2/AKT axis
inhibits epithelial ovarian cancer cell growth and associates with
good overall survival. Oncotarget. 7:80633–80654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li B, Lu Y, Wang H, Han X, Mao J, Li J, Yu
L, Wang B, Fan S, Yu X, et al: miR-221/222 enhance the
tumorigenicity of human breast cancer stem cells via modulation of
PTEN/Akt pathway. Biomed Pharmacother. 79:93–101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fang G, Liu J, Wang Q, Huang X, Yang R,
Pang Y and Yang M: MicroRNA-223-3p regulates ovarian cancer cell
proliferation and invasion by targeting SOX11 expression. Int J Mol
Sci. 18(pii): E12082017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu J, Jiang N, Shi H, Zhao S, Yao S and
Shen H: miR-28-5p promotes the development and progression of
ovarian cancer through inhibition of N4BP1. Int J Oncol.
50:22362017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shen H, Wang D, Li L, Yang S, Chen X, Zhou
S, Zhong S, Zhao J and Tang J: MiR-222 promotes drug-resistance of
breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1
pathway. Gene. 596:110–118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang DD, Yang SJ, Chen X, Shen HY, Luo LJ,
Zhang XH, Zhong SL, Zhao JH and Tang JH: miR-222 induces adriamycin
resistance in breast cancer through PTEN/Akt/p27kip1 pathway.
Tumour Biol. 37:15315–15324. 2016. View Article : Google Scholar : PubMed/NCBI
|
